Therapy News and Research

RSS

Synthetic progestin linked to breast cancer

Millions of post-menopausal women use hormone replacement therapy (HRT) as a method to reduce symptoms associated with menopause.

2 Apr 2008

Catheter repair of mitral valve improves heart size, symptoms

A catheter-mounted device that acts like a clothespin to clip together the flaps of a leaky heart valve is not only reducing the abnormal backflow of blood from the left ventricle to the left atrium, it is helping to shrink the enlarged, overworked heart and relieving symptoms of fluid overload - all without open-chest surgery.

2 Apr 2008

Study results on novel drug-eluting stent coated with a biodegradable polymer

"Real-world" use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry.

1 Apr 2008

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics

Results of a randomised trial published in PLoS Medicine show no benefit in cognitive or neuropsychiatric outcomes from continuing neuroleptic drugs in patients with Alzheimer's disease.

1 Apr 2008

New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients

A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) today to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.

1 Apr 2008

Diabetics have same risk for heart attack, stroke or death from cardiovascular diseases

People with diabetes have the same high risk for heart attack or stroke or cardiovascular death as people who've already had a heart attack, researchers reported in Circulation: Journal of the American Heart Association.

1 Apr 2008

Childhood leukemia survivors struggle with long-term comorbidities

Survival rates of childhood cancers, especially leukemia, have improved greatly in the past three decades, but survivors of this disease still seem to face many health and lifestyle challenges as young adults.

1 Apr 2008

Replacing absent microRNAs could make tumors less invasive, more treatable

One group of small, non-coding RNA molecules could serve as a marker to improve cancer staging and may also be able to convert some advanced tumors to more treatable stages, report a University of Chicago-based research team in the April 1, 2008, issue of the journal Genes & Development.

1 Apr 2008

New blood pressure drug telmisartan has fewer side effects

A major Canadian-led global study has found that a new blood pressure medication is effective in reducing cardiovascular death, with fewer side effects than the current standard of care.

1 Apr 2008

Naglazyme approved in Japan

BioMarin Pharmaceutical Inc. has announced that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing Application for Naglazyme(R) (galsulfase) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with Mucopolysaccharidosis VI ( MPS VI).

1 Apr 2008

Matrix registry probes adherence to clopidogrel at 1 year

A large community-based registry of patients treated with drug-eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors' orders to take clopidogrel, a drug that prevents unwanted blood clots; why they stop taking the drug; and the long-term consequences of that decision.

1 Apr 2008

Researchers publish MRI images of genes in action in the living brain

Biologists have just confirmed what poets have known for centuries: eyes really are windows of the soul—or at least of the brain.

1 Apr 2008

Normal sex duration

Satisfactory sexual intercourse for couples lasts from 3 to 13 minutes, contrary to popular fantasy about the need for hours of sexual activity, according to a survey of U.S. and Canadian sex therapists.

1 Apr 2008

Two drug combo blood pressure therapy lowers cardiovascular risk

An international blood pressure study comparing two single-pill drug combinations has yielded results so significant that the study has been stopped early and the researchers say their findings might alter the way high blood pressure is treated worldwide.

1 Apr 2008

Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use

The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.

31 Mar 2008

Study gives nod to drug-eluting stents in heart attack

Although drug-eluting stents have become widely used for the treatment of stable coronary artery disease, many cardiologists choose bare-metal stents for patients with heart attack, or myocardial infarction (MI), citing conflicting data about the safety and effectiveness of drug-eluting stents in this patient group.

31 Mar 2008

Gene mutations tied to immune comeback during therapy for HIV-1

A new study by U.S. scientists provides compelling evidence that two genes are linchpins in defining the course of immune restoration in HIV-positive individuals undergoing virus-suppressing therapy.

31 Mar 2008

Epilepsy advocates propose strategies to heighten treatment expectations

On the heels of the nation's largest event dedicated to the epilepsy community, the National Walk for Epilepsy, advocates today announced their recommendations in response to a new national survey uncovering key challenges facing the epilepsy community.

31 Mar 2008

Comparison of anticoagulants for angioplasty show similar outcomes

In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology.

31 Mar 2008